As the FDA's May 2026 guidance on AI in drug manufacturing takes effect and a new pilot program offers sponsors extra CMC-focused meetings, the pressure is on to modernize regulatory workflows.
CHICAGO – Several initiatives in the works among regulators and the pharmaceutical industry are gaining momentum to harmonize chemistry, manufacturing, and controls (CMC) information submitted in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results